Pacer Advisors
MIRM icon

Pacer Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Pacer Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-392
Closed -$13.4K – 2639
2024
Q2 		$13.4K Sell
392
-848
-68% -$22.2K ﹤0.01% 3504
2024
Q1 		$31.1K Buy
+1,240
New +$34.1K ﹤0.01% 3347

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pacer Advisors's MIRM Position: Q3 2024 in Review

Pacer Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q3 2024, closing a stake of 392 shares — an estimated $13.4K sold.

Pacer Advisors first reported a position in MIRM in Q1 2024 and held it in 2 quarters. The position peaked at $31.1K in Q1 2024. 178 funds tracked by Wall St. Rank hold MIRM as of Q3 2024.

  • Pacer Advisors reported no remaining Mirum Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 392 Mirum Pharmaceuticals shares in Q3 2024, an estimated $13.4K.
  • Pacer Advisors first reported a position in Mirum Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Mirum Pharmaceuticals position peaked at $31.1K in Q1 2024.
  • 178 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.